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Immunohistochemical expression of 
p53, p16 and hTERT in oral squamous 
cell carcinoma and potentially 
malignant disorders
Abstract: Oral carcinogenesis is a multi-step process. One possible step 
is the development of potentially malignant disorders known as leukopla-
kia and erytroplakia. The objective of this study was to use immunohisto-
chemistry to analyze the patterns of expression of the cell-cycle regulato-
ry proteins p53 and p16INK4a in potentially malignant disorders (PMD) of 
the oral mucosa (with varying degrees of dysplasia) and in oral squamous 
cell carcinomas (OSCC) to correlate them with the expression of telomer-
ase (hTERT). Fifteen PMD and 30 OSCC tissue samples were analyzed. 
Additionally, 5 cases of oral epithelial hyperplasia (OEH) were added to 
analyze clinically altered mucosa presenting as histological hyperplasia 
without dysplasia. p53 positivity was observed in 93.3% of PMD, in 
63.3% of OSCC and in 80% of OEH. Although there was no correlation 
between p53 expression and the grade of dysplasia, all cases with severe 
dysplasia presented p53 suprabasal immunoexpression. p16INK4a expres-
sion was observed in 26.7% of PMD, in 43.3% of OSCC and in 2 cases 
of OEH. The p16INK4a expression in OEH, PMD and OSCC was unable 
to differentiate non-dysplastic from dysplastic oral epithelium. hTERT 
positivity was observed in all samples of OEH and PMD and in 90% of 
OSCC. The high hTERT immunoexpression in all three lesions indicates 
that telomerase is present in clinically altered oral mucosa but does not 
differentiate hyperplastic from dysplastic oral epithelium. In PMD of the 
oral mucosa, the p53 immunoexpression changes according to the degree 
of dysplasia by mechanisms independent of p16INK4a and hTERT.
Descriptors: Mouth Neoplasms; Tumor Suppressor Protein p53; Cyclin-
Dependent Kinase Inhibitor p16; Telomerase.
Introduction
Oral carcinogenesis is a multi-step process involving gene mutations 
and chromosomal abnormalities.1 The transition from normal oral epi-
thelium to oral dysplasia and cancer results from accumulated genetic 
and epigenetic alterations.2 Common early events associated with poten-
tially malignant disorders (PMD) of the oral mucosa include inactivation 
of the tumor suppressor genes TP53 and CDKN2A.1,2 Point mutations 
in TP53 occur in 10-17% of PMD and in 35-67% of oral squamous 
cell carcinoma (OSCC).3 In PMD, a suprabasal p53 immunohistochemi-
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cal staining has been considered to be predictive 
for malignant transformation and progression to 
OSCC.3 p53 expression in OSCC apparently does 
not correlate with differentiation grade but has been 
associated with patient outcome.4,5
The CDKN2A gene is inactivated in approxi-
mately 70% of human cancers.6 Its codified protein 
p16INK4a is a cell-cycle inhibitor that acts in the pRb-
p16INK4a tumor suppressive pathway.6 Both PMD 
and OSCC have been linked to inactivation of the 
CDKN2A gene by homozygous deletion.7
Other mechanisms may also contribute to dys-
plastic cell clonal expansion and tumor progression, 
such as the ability of cells to regain the capacity 
to overcome growth arrest by rebuilding telomeric 
DNA.7,8 Telomeres are chromatin structures that 
cap the ends of eukaryotic chromosomes and ensure 
chromosome stability.8 At each DNA replication 
cycle, 30-150 base pairs of telomeric DNA are lost, 
driving cells into a metabolic state of irreversible 
growth arrest and replicative senescence.8 Telomer-
ase is the enzyme in charge of rebuilding telomeres 
and is not expressed in normal somatic cells.7,8 The 
expression of telomerase in transformed oral epithe-
lial cells could contribute to clonal expansion and to 
overcoming irreversible growth.8
Approximately 90% of primary human cancers 
show telomerase activity, evidenced by expression 
of the enzyme’s catalytic subunit, hTERT (human 
telomerase reverse transcriptase), which is encoded 
by the TERT gene.9 However, the role of telomerase 
in oral carcinogenesis is unknown.10
The purpose of this study was to investigate p53, 
p16 INK4a and hTERT immunohistochemical expres-
sion in PMD of the oral mucosa and OSCC and to 
evaluate correlations between their expression levels 
in these lesions.
Material and Methods
Tissue Samples
Fifty formalin-fixed, paraffin-embedded biopsy 
specimens were retrieved from the Oral Pathology 
and Diagnosis Department of Federal University 
of Rio de Janeiro and from the Pathology Depart-
ment of Fluminense Federal University archives. The 
samples used were 15 potentially malignant disor-
ders (PMD) and 30 oral squamous cell carcinomas 
(OSCC). The lesions were classified according to 
World Health Organization criteria.1,11 Five oral epi-
thelial hyperplasia (OEH) samples were also added 
to the study to analyze hyperplastic oral mucosa 
without dysplasia. The PMD were clinically identi-
fied as leukoplakia or erytroplakia and were graded 
according to the presence of epithelial dysplasia as 
mild, moderate or severe.1,11 The OSCC were classi-
fied as well-differentiated (WD) or poorly differenti-
ated (PD).1 Patients’ clinical data are summarized in 
Table 1.
Table 1 - Patients’ clinical data.
Clinical data
Lesion
OEH
(n = 5)
PMD (n = 15) OSCC (n = 30)
Mild
(n = 5)
Moderate
(n = 8)
Severe
(n = 5)
WD
(n = 17)
PD
(n = 13)
Mean age 60 63.4 68.2 62.5 59.1 65.25
Gender
Female  3 (60%) 4 (80%) 2 (40%) 3 (60%)  6 (35.3%) 4 (30.77%)
Male  2  (40%) 1 (20%) 3 (60%) 2 (40%) 11 (64.7%) 9 (69.23%)
Site
Tongue  0 2 (40%) 1 (20%) 2 (40%) 8 (47.06%) 3 (23.08%)
Buccal mucosa  0 1 (20%) 3 (60%)  0 3 (17.65%)  1 (7.69%)
Floor of the mouth  0  0  0 1 (20%) 2 (11.76%) 3 (23.08%)
Gingiva/alveolar ridge 5 (100%) 2 (40%) 1 (20%) 2 (40%) 3 (17.65%) 6 (46.15%)
Palate  0  0  0  0  1 (5.88%)  0
OEH = oral epithelial hyperplasia; PMD = potentially malignant disorders; OSCC = oral squamous cell carcinoma; WD = well-differentiated; PD = poorly 
differentiated.
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Immunohistochemistry
The streptavidin-biotin standard protocol was 
performed. Paraffin-embedded tissues were cut into 
3 µm thick sections, placed over slides, deparaf-
finized in xylene and rehydrated in graded alcohol. 
Antigen retrieval was performed with Target antigen 
retrieval solution pH 9 (Dako A/S, CA, USA) in a 
water bath, followed by incubation with 6% hydro-
gen peroxide to quench endogenous peroxidase. The 
sections were then incubated in blocking solution 
(3% bovine serum albumin) for 1 hour at room tem-
perature, followed by primary antibody incubation, 
previously diluted in blocking solution. Anti-p53 
(clone DO-7, 1:200 dilution – DAKO A/S, CA, USA) 
and anti-hTERT (Novocastra, clone 44F12, 1:75 
dilution - Leica Microsystems, Berlin, Germany) an-
tibodies were incubated for 30 minutes at room tem-
perature, and the p16INK4a antibody (CINtecTM His-
tology kit, clone E6H4, 1:250 dilution – DAKO A/S, 
CA, USA) was incubated overnight at 4°C. Sections 
were exposed to the LSABTM system (DAKO A/S, 
CA, USA), developed in diaminobenzidine (Dako 
A/S, CA, USA) and counterstained in Mayer’s he-
matoxylin.
Positive immunohistochemistry expression of 
p53, p16INK4a and hTERT was defined by a nuclear, 
nuclear and cytoplasmic, and nuclear (evidenced by 
nucleolar positivity) staining pattern of epithelial 
cells, respectively. The results are expressed in both 
the number of positive cases and the percentage of 
immunostained cells after counting 100 cells in 10 
consecutive high-power fields. p53 labeling in OEH 
and PMD was also evaluated as described previous-
ly by Cruz et al.:3 basal when confined to the basal 
layer; and suprabasal when both basal and supra-
basal layers were positive.
Pearson correlation, Fisher’s exact test, Kruskall-
Wallis and Mann Whitney tests were used for statis-
tical analysis, and were performed with GraphPad 
Prism 5.00 (GraphPad Software, CA, USA). A p 
value less than 0.05 (p < 0.05) was considered statis-
tically significant.
Results
The immunohistochemical results of p53, 
hTERT and p16INK4a in OEH, PMD and OSCC are 
summarized in Table 2. Positive p53 cases were a 
common event in all study groups. In 7 PMD and in 
the entire OEH group, a basal p53 staining pattern 
was found (Figure 1). An additional 7 cases of PMD 
showed a suprabasal p53 staining pattern (Figure 
1). There was no statistical difference between dys-
plasia degree and staining pattern in PMD samples. 
p53 positivity was also frequent in OSCC (Figure 2). 
No statistical difference was found between well-
differentiated and poorly differentiated OSCC cases 
(p > 0.05).
Positive hTERT immunostained nuclei were ob-
served through all epithelial cell layers in OEH and 
PMD (Figure 1). In the latter, no distinction was 
found between dysplasia grades and hTERT posi-
tivity (p  >  0.05). The majority of the OSCC cases 
were positive for hTERT staining (Figure 2), and no 
differences were found between WD and PD OSCC 
samples (p > 0.05).
Positive p16INK4a immunostaining in OEH and 
Table 2 - Distribution of positive cases in oral epithelial hyperplasia (OEH), potentially malignant disorders (PMD) and oral 
squamous cell carcinoma (OSCC), in accordance to p53, p16 INK4a and hTERT.
Lesion
antibody
OEH
(n = 5)
PMD OSCC
Mild
(n = 5)
Moderate
(n = 5)
Severe
(n = 5)
Total
(n = 15) 
WD
(n = 17)
PD
(n = 13)
Total
(n = 30)
p53
Ba  4 (80%) 2 (13.3%) 5 (33.3%) 0  7 (46.6%)
12 (40%)  7 (23.3%)  19 (63.3%)
SBb 0  2 (3.3%) 0 5 (33.3%)  7 (46.6%)
hTERT  5 (100%) 5 (33.3%) 5 (33.3%) 5 (33.3%)  15 (100%) 15 (50%) 12 (40%) 27 (90%)
p16INK4a  2 (40%) 2 (13.3%) 2 (13.3%) 0  4 (26.6%)  7 (23.3%)  6 (20%)  13 (43.3%)
aBasal cell layer; bSuprabasal cell layer
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PMD showed stained cells arranged in clusters with 
skip areas in basal and suprabasal epithelial cell 
layers (Figure 1). No correlation between dysplasia 
grade and p16INK4a was observed (p > 0.05). In the 
OSCC group, positive p16INK4a cases were uncom-
mon and two staining patterns were identified. Ten 
cases presented positive cells organized in small iso-
lated clusters, and the remaining three presented 
extensive sheets of immunostained cells (Figure 2). 
There was no correlation between p16INK4a immu-
noexpression with WD or PD OSCC histological 
grades (p > 0.05).
In the PMD group, the immunohistochemical 
expression of p53 and p16INK4a was not correlated 
(p > 0.05). This study group presented higher means 
of hTERT positive cells (85.5) compared to p53 
(35.6; p  <  0.0001) and p16INK4a positive cells (5.5; 
p < 0.0001). The OSCC cases did not show correla-
tion between the three antibodies (p > 0.05). How-
ever, this group presented a significant difference 
when the means of p16INK4a positive cells (18.8) were 
compared to p53 (56.7; p < 0.001) and hTERT posi-
tive cells (66.7; p < 0.0001).
Figure 1 - Protein IHC 
expression in PMD. A: p53 
expression in basal epithelial 
cell layer; B: p53 expression in 
suprabasal epithelial cell layers; 
C: p16INK4a expression in small 
cell groups; D: hTERT expression 
throughout epithelial cell layers. 
(SAB - original magnification 
200x).
A
C
B
D
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Discussion
Long-term retrospective reports have demon-
strated that higher transformation rates to oral 
squamous cell carcinoma are not necessarily linked 
to severe grades of dysplasia.12,13 Also, reliable histo-
logical grading systems and prognostic markers are 
lacking for OSCC.14
In normal oral epithelium, p53 is restricted to 
the proliferative basal cell layer.3 Overexpression 
of inactivated or mutated forms of p53 in oral epi-
thelial dysplasia has been associated with high risk 
for transformation to early stage OSCC.4 Cruz et 
al. showed that suprabasal p53 immunoexpression 
patterns are associated with high grades of dyspla-
A
DC
F
B
E
Figure 2 - Protein IHC expression in OSCC. A and B: p53 in WD and PD cases; C: p16INK4a focal expression in a WD case; 
D: p16INK4a overexpression in a PD case; E and F: hTERT in WD and in PD cases. (SAB - original magnification 400x).
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sia and correlate with progress to oral squamous cell 
carcinoma.3 According to the authors, expression 
pattern should be considered a predictive marker 
for malignant transformation, although malignant 
transformation also occurs in the absence of supra-
basal p53 staining or dysplastic changes.3 In this 
study, p53 suprabasal expression was found in 2 
cases of mild dysplasia and in all 5 severe dyspla-
sia samples. No statistical significance was found 
among histological grades, possibly due to the small 
number of cases studied. However, suprabasal p53 
immunoexpression may be a useful tool for malig-
nant transformation risk assessment of potentially 
malignant disorders independent of dysplasia grade. 
Further studies with follow up are necessary to con-
firm this assumption.
p53 has been detected in a large percentage of 
OSCC cases by immunohistochemistry, reflecting 
the altered status of this protein.15 More than 50% 
of our OSCC samples were p53 positive in accor-
dance with the results described in the literature. 
Although we detected more cases of p53 positive 
WD-OSCC compared to PD-OSCC, this difference 
was not significant. Previous reports are inconclu-
sive when relating p53 immunoexpression with the 
differentiation grade of OSCC.5,15
Inactivation of the p16INK4a gene is frequently 
identified during early carcinogenesis. However, 
non-dysplastic mucosa and oral dysplastic lesions of-
ten lack positive p16INK4a immunohistochemical ex-
pression.16,17 Perhaps this lack of positive staining re-
flects that in non-dysplastic oral epithelium, normal 
p16INK4a protein is below detection levels, whereas in 
epithelial dysplasia, the low expression is related to 
gene inactivation.12 The significance of p16INK4a im-
munoexpression in OSCC is unknown but has been 
correlated with response to therapy, prognosis and 
tumor morphology.18 Among the studied OSCC, 
18.8% were found positive for p16INK4a. The OEH 
and PMD cases were positive in scattered groups of 
cells. These results suggest that p16INK4a is unrelated 
to the degree of dysplasia, although the small num-
ber of positive cases occurred in samples with mild 
and moderate dysplasia. These results may reflect 
either the frequent genetic inactivation of p16INK4a 
in early phases of carcinogenesis or the p16INK4a ex-
pression in slow cycling progenitor cells.19
Angiero et al. demonstrated an increase in 
p16INK4a expression in higher grades of dysplasia and 
invasive OSCC.20 Likewise, Gologan et al. showed 
that p16INK4a immunoexpression was able to high-
light dysplastic areas in oral epithelium.16 However, 
Bradley et al. showed a significant trend toward ab-
sent expression of p16INK4a with increasing dysplasia 
severity.12 These different results are possibly due to 
the methodology or antibody used in the study. Oth-
er aspects that may influence immunohistochemical 
detection of p16INK4a in OSCC are related to etio-
logical factors. Different cancer-causing agents may 
lead to p16INK4a gene inactivation as well as altered 
p53 and pRb tumor suppressive pathways.5,17 These 
changes may result in either loss or overexpression 
of p16INK4a in oral dysplasia and OSCC. HPV onco-
genes are frequently found in oropharyngeal squa-
mous cell carcinomas that display concomitant in-
creased p16INK4a expression.17,21,22 According to Vidal 
and Gillison, patients with HPV-positive head and 
neck squamous cell carcinoma present better clini-
cal outcomes compared to those with HPV-negative 
tumors.22 Our study shows thirteen OSCC with 
p16INK4a expression, and viral participation cannot 
be discarded. Other relevant etiopathological agents 
that may influence p16INK4a expression are smoking 
and smoke-less tobacco use.21,23 The oral mucosa 
of smokers and lesions associated with smoke-less 
tobacco use express p16INK4a more frequently when 
compared to individuals that do not use tobacco.20,21
Telomerase activation is reported as a common 
event in oral carcinogenesis, and hTERT expression 
has been detected in epithelial cells of dysplastic oral 
mucosa.10 Low levels of hTERT mRNA have been 
reported in normal oral mucosa, with a gradual 
increase during malignant transformation.7 In the 
current investigation, all OEH and PMD cases were 
hTERT positive, and no correlation was found be-
tween hTERT and dysplasia grade. We suggest that 
the intense hTERT staining in the OEH and PMD 
groups may reflect a high proliferative cell capacity 
in oral lesions with epithelium presenting as hyper-
plasia and dysplasia. In normal oral epithelium, the 
hTERT expression is reported to be low when com-
pared to hyperplastic or dysplastic oral epithelium.24 
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In oral carcinogenesis, telomerase expression may 
favor telomere stabilization and cell proliferation.
Telomerase activity is important in deregulated 
cell growth and escape from senescence, contrib-
uting to clonal expansion of dysplastic cells that 
harbor p53 and p16INK4a abnormalities.19,24 Chen et 
al. showed a correlation between cytoplasmic and 
nuclear hTERT expression in histologically differ-
ent OSCC, suggesting that hTERT expression was 
a biomarker for this type of lesion.24 The authors 
reported that cytoplasmic hTERT was increased in 
dysplastic oral epithelium and OSCC compared to 
normal epithelium, whereas nuclear hTERT was 
decreased in OSCC.24 This work analyzed nuclear 
hTERT staining and found a higher hTERT expres-
sion in WD-OSCC compared to PD-OSCC. The 
mean number of hTERT positive cells in the WD 
group had a tendency to be higher than in the PD 
group. It is possible that in PD-OSCC, other mecha-
nisms are involved in maintaining telomere length 
such as alternative lengthening of telomeres. Future 
studies are needed to help clarify the contribution of 
telomere lengthening and telomere-associated pro-
teins in oral carcinogenesis.
Conclusion
p53, p16INK4a and hTERT are not associated with 
the grade of dysplasia in PMD of the oral mucosa 
or with the differentiation degree of OSCC. How-
ever, suprabasal p53 immunoexpression was associ-
ated with severe grades of dysplasia. The results also 
show that p16INK4a may not be useful for distinguish-
ing hyperplastic oral epithelium from dysplastic oral 
epithelium. The intense hTERT expression in OEH, 
PMD and OSCC suggests that telomerase activity is 
involved in the development of hyperplastic and dys-
plastic oral epithelium.
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